53578-U

Ascentis^® Express 90 Å F5 (2.7 μm) HPLC Columns

L × I.D. 10 cm × 3 mm, HPLC Column

• 別名: Core-shell (SPP) Fused Core PFP HPLC column
• UNSPSCコード: 41115700
• eCl@ss: 32110501
• NACRES: SB.52

特性

• product name: Ascentis^® Express F5、2.7 μm HPLCカラム, 2.7 μm particle size, L × I.D. 10 cm × 3 mm
• 物質: stainless steel column
• 認証: suitable for USP L43
• 製品種目: Ascentis^®
• 特徴: endcapped
• メーカー／製品名: Ascentis^®
• 包装: 1 ea of
• パラメーター: 60 °C temp. range; 600 bar max. pressure (9000 psi)
• テクニック: HPLC: suitable; LC/MS: suitable; UHPLC-MS: suitable; UHPLC: suitable
• L × 内径: 10 cm × 3 mm
• 表面積: 135 m²/g
• 不純物: <5 ppm metals
• マトリックス: Fused-Core particle platform; superficially porous particle
• マトリックス活性基: PFP (pentafluorophenyl) phase
• 粒径: 2.7 μm
• ポアサイズ: 90 Å pore size
• 使用pH: 2-8
• アプリケーション: food and beverages
• 分離法: reversed phase

詳細

詳細

Ascentis Express F5のペンタフルオロフェニルプロピル固定相は、電気陰性フッ素の存在のため電子不足フェニル環を持つ安定な逆相充填剤となります。pi-pi相互作用とマイルドな立体的相互作用の形成に加え、F5固定相は極性相互作用により化合物を保持します。Ascentis Express F5は、C18由来の交互選択性により塩基性、酸性、または中性の化合物で使用できます。

アプリケーション

• Liquid chromatographic determination of lumacaftor in the presence of ivacaftor and identification of five novel degradation products using high-performance liquid chromatography ion trap time-of-flight mass spectrometry.: This study employs the Ascentis^® Express F5, 2.7 μm HPLC Column to enhance the resolution and sensitivity in the analysis of lumacaftor and ivacaftor, critical medications for treating cystic fibrosis. The method provides significant insights into the stability and degradation pathways of these drugs, facilitating improved drug formulation and storage conditions (Ozcan et al., 2023).
• Stability-indicating LC-MS/MS and LC-DAD methods for robust determination of tasimelteon and high resolution mass spectrometric identification of a novel degradation product.: Utilizing the Ascentis^® Express F5, 2.7 μm HPLC Column, this research develops advanced analytical techniques for tasimelteon, a treatment for non-24-hour sleep-wake disorder. The methods ensure accurate quantification and stability assessment, crucial for clinical efficacy and patient safety (Ozcan et al., 2020).

法的情報

Ascentis is a registered trademark of Merck KGaA, Darmstadt, Germany

安全性情報

• 保管分類コード: 11 - Combustible Solids
• WGK: WGK 3
• 引火点(°F): Not applicable
• 引火点(℃): Not applicable